317953
Estimating the Economic Burden of Alzheimer's Disease and Other Dementias in San Diego County
Lifetime costs included direct and indirect medical costs and the average length of survival after ADOD diagnosis, coming to $27 billion. Hospitalization costs were determined using California Department of Public Health Patient Discharge Data. There were nearly 17,000 hospitalizations with any mention of ADOD, accounting for $886 million in direct charges. Lastly, caregiving estimates were determined using national and state estimates adjusted for San Diego County based on estimated ADOD prevalence. More than 136,800 San Diegans provided 156 million hours of unpaid care, worth $1.94 billion. Health care costs to caregivers due to impacts of caregiving were $75.4 million.
Estimating the economic burden ADOD places on social and health care systems is important for policy and program planning. The methods used in San Diego County can be applied in other jurisdictions to estimate the economic burden of ADOD. This information is essential for leading informed discussions and making data driven decisions when planning for the increase in residents living with ADOD.
Learning Areas:
Public health or related researchLearning Objectives:
List the many conditions included in the definition of Alzheimer's disease and other dementias
Identify the types of costs used to calculate the econonomic burden of Alzheimer's disease and other dementias
Keyword(s): Economic Analysis, Dementia
Qualified on the content I am responsible for because: I led the research team and developed the modeling used in this project. I am the Senior Epidemiologist for County of San Diego HHSA and served as the lead scientist for the Alzheimer's Disease and Other Dementias project. I manage the Community Health Statistics Unit. I hold graduate degrees in public health, public policy and educational psychology as well as a post graduate certificate in Health Economics and Outcomes Research.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.